Sold as Declomycin. Every FDA application for this active ingredient: 3 branded and 5 generic.
As of Nov 16, 2026, FDA lists 8 applications for Demeclocycline Hydrochloride (sold as Declomycin), first approved Jan 14, 1960, with 5 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Demeclocycline HCl | Part D | $3.5M | -22% | 1,657 |
| Jan 14, 1960 | DeclomycinNDA 50262 | Lederle | 53 | Discontinued |
| Nov 14, 1960 | DeclomycinNDA 50257 | Lederle | 52 | Discontinued |
| Sep 22, 1964 | DeclomycinNDA 50261 | Corepharma | 87 | Discontinued |
| Mar 22, 2004 | Demeclocycline HydrochlorideANDA 65094 | Impax Labs | 0 | Discontinued |
| Dec 13, 2004 | Demeclocycline HydrochlorideANDA 65171 | Barr | 2 | Discontinued |
| Feb 27, 2008 | Demeclocycline HydrochlorideANDA 65425 | Amneal Pharm | 1 | Marketed |
| Dec 1, 2008 | Demeclocycline HydrochlorideANDA 65389 | Epic Pharma LLC | 1 | Marketed |
| Aug 18, 2015 | Demeclocycline HydrochlorideANDA 65447 | Epic Pharma LLC | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA